Sofinnova Investments, Inc. Syndax Pharmaceuticals Inc Transaction History

Sofinnova Investments, Inc.

$1.06 Billion
Q3 2024

A detailed history of Sofinnova Investments, Inc. transactions in Syndax Pharmaceuticals Inc stock. As of the latest transaction made, Sofinnova Investments, Inc. holds 786,999 shares of SNDX stock, worth $12.6 Million. This represents 1.43% of its overall portfolio holdings.

Number of Shares

786,999

Previous 2,153,669 63.46%

Holding current value

$12.6 Million

Previous $44.2 Million 65.74%

% of portfolio

1.43%

Previous 2.45%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 13, 2024	SELL	$17.93 - $24.81 $24.5 Million - $33.9 Million	-1,366,670 Reduced 63.46%	786,999 $15.1 Million
Q2 2024 Aug 09, 2024	BUY	$18.82 - $23.79 $10.3 Million - $13 Million	545,129 Added 33.89%	2,153,669 $44.2 Million
Q1 2024 Aug 14, 2024	SELL	$19.71 - $24.57 $10.7 Million - $13.4 Million	-545,129 Reduced 25.31%	1,608,540 $38.3 Million
Q1 2024 May 15, 2024	BUY	$19.71 - $24.57 $10.5 Million - $13.1 Million	532,754 Added 49.52%	1,608,540 $38.3 Million
Q4 2023 Aug 15, 2024	SELL	$11.39 - $21.67 $12.3 Million - $23.4 Million	-1,077,883 Reduced 50.05%	1,075,786 $23.2 Million
Q4 2023 Feb 12, 2024	SELL	$11.39 - $21.67 $5.77 Million - $11 Million	-506,505 Reduced 32.01%	1,075,786 $23.2 Million
Q2 2023 Aug 14, 2023	BUY	$19.35 - $22.31 $9.81 Million - $11.3 Million	506,867 Added 47.13%	1,582,291 $33.1 Million
Q1 2023 May 11, 2023	BUY	$20.66 - $28.98 $7.69 Million - $10.8 Million	372,350 Added 52.96%	1,075,424 $22.7 Million
Q4 2022 Feb 13, 2023	BUY	$20.64 - $26.24 $3.68 Million - $4.67 Million	178,072 Added 33.92%	703,074 $17.9 Million
Q3 2022 Nov 08, 2022	BUY	$18.51 - $24.79 $2.07 Million - $2.77 Million	111,574 Added 26.99%	525,002 $12.6 Million
Q2 2022 Aug 15, 2022	SELL	$13.64 - $19.48 $4.14 Million - $5.91 Million	-303,636 Reduced 42.34%	413,428 $7.95 Million
Q1 2022 May 16, 2022	SELL	$14.84 - $22.15 $3.47 Million - $5.19 Million	-234,162 Reduced 24.62%	717,064 $12.5 Million
Q4 2021 Feb 14, 2022	BUY	$15.23 - $22.47 $8.18 Million - $12.1 Million	537,385 Added 129.85%	951,226 $20.8 Million
Q3 2021 Nov 15, 2021	BUY	$13.87 - $19.8 $5.74 Million - $8.19 Million	413,841 New	413,841 $7.91 Million
Q2 2021 Aug 16, 2021	SELL	$13.42 - $25.18 $4.01 Million - $7.52 Million	-298,644 Closed	0 $0
Q1 2021 May 14, 2021	SELL	$19.28 - $24.59 $1.43 Million - $1.83 Million	-74,265 Reduced 19.92%	298,644 $6.68 Million
Q4 2020 Feb 16, 2021	BUY	$15.1 - $26.44 $5.63 Million - $9.86 Million	372,909 New	372,909 $8.29 Million
Q3 2020 Nov 13, 2020	SELL	$13.39 - $17.48 $1.23 Million - $1.61 Million	-91,964 Closed	0 $0
Q2 2020 Aug 13, 2020	BUY	$8.94 - $20.98 $822,158 - $1.93 Million	91,964 New	91,964 $1.36 Million
Q4 2019 Feb 14, 2020	SELL	$5.43 - $9.22 $1.32 Million - $2.24 Million	-243,150 Closed	0 $0
Q3 2019 Nov 14, 2019	BUY	$7.47 - $10.76 $3,144 - $4,529	421 Added 0.17%	243,150 $1.82 Million
Q2 2019 Aug 13, 2019	BUY	$4.9 - $9.31 $143,913 - $273,434	29,370 Added 13.77%	242,729 $2.26 Million
Q1 2019 May 15, 2019	SELL	$4.26 - $6.86 $582,559 - $938,111	-136,751 Reduced 39.06%	213,359 $1.12 Million
Q4 2018 Feb 14, 2019	BUY	$3.6 - $8.42 $637,192 - $1.49 Million	176,998 Added 102.24%	350,110 $1.56 Million
Q3 2018 Nov 15, 2018	BUY	$6.33 - $8.08 $471,578 - $601,951	74,499 Added 75.55%	173,112 $1.4 Million
Q2 2018 Nov 15, 2018	BUY	$6.93 - $14.63 $597,774 - $1.26 Million	86,259 Added 698.23%	98,613 $693,000
Q2 2018 Aug 14, 2018	BUY	$6.93 - $14.63 $1,593 - $3,364	230 Added 1.9%	12,354 $87,000
Q1 2018 May 15, 2018	BUY	$8.71 - $14.82 $105,600 - $179,677	12,124 New	12,124 $173,000

Others Institutions Holding SNDX

# of Institutions

227

Shares Held

88.3M

Call Options Held

1.01M

Put Options Held

692K

View Full List

About Syndax Pharmaceuticals Inc

Ticker SNDX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 56,565,200
Market Cap $902M
Description
Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613, which is in phase 1/2 clinical trial targeting the binding interaction of Menin with the mixed lineage leukemia 1 protein for the treatment of MLL-rearranged (MLLr) and nucleophosmin...

More about SNDX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Sofinnova Investments, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Sofinnova Investments, Inc. with notifications on news.

Account

Sofinnova Investments, Inc. Syndax Pharmaceuticals Inc Transaction History